Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin in CD30-positive Hematologic Malignancies
NCT00947856Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Jul 2009
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of brentuximab vedotin in Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), non-Hodgkin lymphoma (NHL), sponsored by Seagen Inc.. Started Jul 2009; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)anaplastic large cell lymphoma (ALCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00947856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00947856.